Navigation Links
Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Date:1/9/2009

CHADDS FORD, Pa., Jan. 9 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that David Holveck, President and Chief Executive Officer of Endo, will present a corporate update at the J.P. Morgan 27th Annual Healthcare Conference on Wednesday, January 14, 2009 at 10:30 a.m. Pacific Time. The conference will be held January 12-15, 2009 in San Francisco.

A link to a live audio Webcast of the presentation may be accessed on the Endo Website at www.endo.com. The presentation will be archived for ninety days.

About Endo Pharmaceuticals

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.

'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 3, 2015 Forskere ... 2015 på  http://www.openinnovationinscience.at om efteruddannelsesprogrammet "Lab ... sted i Wien .  ... internationale forskere og videnskabsmænd foretaget af Ludwig ... udfordringer for sundhedsvidenskaben manglen på incitamenter til ...
(Date:7/2/2015)... , July 2, 2015  Spherix Incorporated (Nasdaq: ... fostering and monetization of intellectual property, today announced a ... Spherix Incorporated v. Verizon Services Corp. et al. , ... for the Eastern District of Virginia ... 1, 2015 interpreting certain key claims in favor of ...
(Date:7/2/2015)... ... 2015 , ... In’Tech Medical SAS ( http://www.intech-medical.com ), a ... the acquisition of Turner Medical, Inc ., thus becoming a global leader ... Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech Medical’s product offering, ...
(Date:7/1/2015)... , July 1, 2015   Decision Resources ... cited advantages of Otezla are its oral administration, ... as reported by surveyed rheumatologists. Otezla was the ... the treatment of active psoriatic arthritis in ... standard of care includes conventional oral treatments including ...
Breaking Biology Technology:Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3
... Cell Therapeutics, Inc. (the "Company" or "CTI") (Nasdaq and ... its "Modified Dutch Auction" tender offer to a fixed price ... million outstanding principal amount of five series of its convertible ... offer for a combined aggregate principal amount of Notes, the ...
... , NEW YORK, June 2 Cynvec LLC, a ... therapies that harness the apoptotic ability of the sindbis ... Chief Executive Officer, will make a presentation titled "Cynvec: ... 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical ...
... Inc. (Nasdaq: AMLN ) today announced that ... the Company,s Annual Meeting of Stockholders held May 27, ... The preliminary tabulation indicates that shareholders voted to ... Board of Directors - Adrian Adams, Steven R. Altman, ...
Cached Biology Technology:Cell Therapeutics Amends and Restates Its 'Modified Dutch Auction' Tender Offer to a Fixed Price Tender Offer for Any and All of Its $118.9 Million Outstanding Convertible Notes 2Cell Therapeutics Amends and Restates Its 'Modified Dutch Auction' Tender Offer to a Fixed Price Tender Offer for Any and All of Its $118.9 Million Outstanding Convertible Notes 3Cell Therapeutics Amends and Restates Its 'Modified Dutch Auction' Tender Offer to a Fixed Price Tender Offer for Any and All of Its $118.9 Million Outstanding Convertible Notes 4Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry 2Amylin Announces Preliminary Tabulation of Annual Meeting Results 2Amylin Announces Preliminary Tabulation of Annual Meeting Results 3
(Date:6/18/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market announces that its Wocket® smart wallet ... on the Mark", scheduled to air on WABC Radio (am770) ... th . The broadcast air- time for ... 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira will ...
(Date:6/16/2015)... 16, 2015 /CNW Telbec/ - handyem Inc. and ... the incorporation of handyem,s HPC-150 portable flow cytometer ... Mo-POD™. This unprecedented model of mobile laboratory platform ... the Pennsylvania Convention Center, ... th to 18 th 2015.  By ...
(Date:6/15/2015)... 2015 A new report [ ... majority of US consumers using mobile banking applications want their ... fingerprint and voiceprint, instead of having to prove who they ... " Mobile Identity   -   The Fusion of Financial ... now the primary channel used by Gen X and Gen ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... primary ingredient of blood clots, creates a fibrous network that ... But beyond this essential work, fibrin can also cause heart ... blood vessels. Fibrin forms when an enzyme removes parts ... into "holes" located on both ends of fibrinogen molecules. Uncovering ...
... release is available in Spanish . ... tubers with red, yellow, orange and purple flesh. This ... scientists in Prosser, Wash., are discovering. Together ... detecting and measuring phytonutrient concentrations in the tubers. Phytonutrients ...
... WASHINGTON, DC May 18, 2010 -- The American ... mBio , a new open access online journal designed ... the journal is on rapid publication of cutting-edge research spanning ... "The microbial world is a highly interconnected one ...
Cached Biology News:New study reveals ways to better inhibit blood clots 2New study reveals ways to better inhibit blood clots 3ASM launches new open access journal 2
... kit for 25 chips provides the chips ... analysis (at nanogram levels) with the Experion ... RNA StdSens microfluidic chips, 2 x 1,250 ... RNA StdSens stain, 2 x 20 microliters ...
...
... is a full featured, two laser, six detector ... Cytometer, CFlow Software, and a PC for operation ... all the capabilities of the best selling flow ... C6 Flow Cytometer System has six detectors to ...
Fingerprinting II Basic software is used for analyzing fingerprint sample types (electrophoretic gels, HPLC and other chromatographic patterns, spectrophotometric and densitometric curves)....
Biology Products: